ENCell announces promising results from Phase 1 CMT1A trial of EN001
ENCell Co., Ltd., a South Korean biotech leader specializing in Cell and Gene Therapy (CGT), has unveiled promising results from their first-in-human Phase 1 clinical trial of EN001, a novel mesenchymal stem cell therapy aimed at treating Charcot-Marie-Tooth disease type 1A (CMT1A). The findings were presented at the Peripheral Nerve Society (PNS) annual meeting held […]